| 引用本文： |
-
周倩倩,陆家睛,胡艺凡,等.他扎罗汀倍他米松乳膏治疗慢性斑块型银屑病的临床疗效和安全性评价[J].同济大学学报（医学版）,2019,40(5):608-612. [点击复制]
- ZHOU Qian-qian,LU Jia-qing,HU Yi-fan,et al.Efficacy and safety of tazarotene betamethasone cream in treatment of chronic plaque psoriasis[J].同济大学学报（医学版）,2019,40(5):608-612. [点击复制]
|
|
| 摘要: |
| 目的 探讨他扎罗汀倍他米松乳膏（含0.05%他扎罗汀和0.05%二丙酸倍他米松）治疗慢性斑块型银屑病的临床疗效和安全性。方法 将90例慢性斑块型银屑病患者随机分为治疗组（45例）和对照组（45例），治疗组外用他扎罗汀倍他米松乳膏，每日1次，睡前应用；对照组外用卡泊三醇软膏，早晚各1次；疗程均为4周。疗程结束后，随访8周。结果 治疗4周后，治疗组的银屑病皮损面积和严重程度指数（psoriasis area severity index, PASI）、医生对病情的总体评估（physician’s global assessment, PGA）和皮肤病生活质量指数（dermatology life quality index, DLQI）均较对照组显著下降，差异有统计学意义（P＜0.05）。治疗组的有效率（65.00%）显著高于对照组（41.46%），差异有统计学意义（P＜0.05）。治疗过程中，两组间不良反应发生率差异无统计学意义（P＞0.05）。随访8周后，治疗组的复发率为23.07%，对照组为29.41%，差异无统计学意义（P＞0.05）。结论 他扎罗汀倍他米松乳膏治疗慢性斑块型银屑病的疗效优于卡泊三醇软膏，不良反应和复发率与卡泊三醇软膏没有差异。 |
| 关键词: 他扎罗汀倍他米松 银屑病 斑块型 临床疗效 安全性 |
| DOI：10.16118/j.1008-0392.2019.05.014 |
| 投稿时间：2019-02-12 |
| 基金项目:国家自然科学基金（81872522、81673050）；上海市科学技术委员会基金（18140901800）；上海市申康医院发展中心专科疾病临床“五新”转化项目（16CR3096B） |
|
| Efficacy and safety of tazarotene betamethasone cream in treatment of chronic plaque psoriasis |
| ZHOU Qian-qian,LU Jia-qing,HU Yi-fan,XU Le-zhen,ZOU Ying,SHI Yu-ling |
| (Dept. of Dermatology, Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200072;Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200072; Dept. of Dermatology, Shanghai Skin Disease Hospital,Shanghai 200072;Unit of Skin and Cosmetics Research, Shanghai Skin Disease Hospital, Shanghai 200072) |
| Abstract: |
| Objective To assess the efficacy and safety of tazarotene betamethasone cream (containing 0.05% tazarotene and 0.05% betamethasone dipropionate) in treatment of chronic plaque psoriasis. Methods Ninety patients with chronic plaque psoriasis admitted in our hospital from June 2017 to June 2018 were randomly divided into two groups: 45 patients in study group were treated with tazarotene betamethasone cream q.n, while 45 patients in control group were treated with calcipotriol ointment b.i.d. The course of treatment was 4 weeks and patients were followed-up for 8 weeks. Results After 4 weeks of treatment the PASI, PGA and DLQI scores of the study group were significantly lower than those of control group (P＜0.05).The effective rate of the study group (65.00%) was higher than that of the control group (41.46%) (P＜0.05). There was no significant difference in the incidence of adverse reactions between two groups (P＞0.05). After 8 weeks of follow-up, the recurrence rate was 23.07% and 29.41% in the study group and control group, respectively (P＞0.05). Conclusion The efficacy of tazarotene betamethasone cream in treatment of chronic plaque psoriasis is better than that of calcipotriol ointment. There is no significant difference in the recurrence rate and incidence of adverse reactions between two drugs. |
| Key words: tazarotene betamethasone psoriasis plaque clinical effect safety |
